Aurobindo Pharma is currently trading at RS. 1118.55, up by 14.55 points or 1.32% from its previous closing of RS. 1104.00 on the BSE.

The stock opened at RS. 1119.90 and touched an intraday high of RS. 1119.90 and a low of RS. 1114.00. So far, 4888 shares have been traded on the counter.

Belonging to BSE group 'A', the stock with a face value of RS. 1 recorded a 52-week high of RS. 1592.55 on September 13, 2024, and a 52-week low of RS. 994.35 on April 7, 2025. The scrip’s one-week high and low stood at RS. 1119.90 and RS. 1079.05 respectively. The company's current market capitalization is RS. 64829.08 crore.

The shareholding pattern shows promoters holding 51.82%, institutions at 41.56%, and non-institutions at 6.61%.

In a significant development, Aurobindo Pharma’s wholly owned step-down subsidiary, CuraTeQ Biologics s.r.o., has received marketing authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Dyrupeg, its pegylated filgrastim biosimilar.

Earlier in April 2025, Dyrupeg received marketing approval from the European Commission (EC) for the European Union market. This marks CuraTeQ’s third biosimilar approval from the MHRA, following Bevqolva in December 2024 and Zefylti in May 2025.

Aurobindo Pharma specializes in manufacturing pharmaceutical products, including active pharmaceutical ingredients (APIs), intermediates, and generic formulations like astemizole, domperidone, and omeprazole. Its product portfolio spans anti-infectives, oral and sterile antibiotics, pain management, and osteoporosis segments.